You know the deal world is getting harder when a state legislature puts a target on your back. If you finally felt you had a handle on Medicare Advantage and managed Medicaid, you now have a few hundred state legislators to figure out as well.
For most of the last thirty years, the risks in healthcare private equity were federal and economic: CMS rate cuts, Medicare Advantage policy, fraud and abuse rules, the occasional antitrust review. States mattered as Medicaid payors and licensing boards. They rarely decided whether a deal could close.
That has changed. In a growing number of states, legislators and regulators now decide how long a healthcare transaction takes to close and how it must be structured. In a few, they decide whether it can close at all. And in one, they have decided that a structure investors already own will soon be illegal. That is a category of risk the industry never had to price.
Oregon moved first and furthest. Under a 2021 law, its Health Care Market Oversight program requires 180 days’ notice before a covered transaction closes and gives the state the power to reject a deal outright. In June 2025 the state went further. Senate Bill 951 prohibits dual ownership and control between MSOs and the physician practices they manage and, with limited exceptions, voids noncompetes that restrict the practice of medicine or nursing. Kirkland & Ellis described it as the nation’s toughest limits on private equity in physician practices.
The catalyst was not a private equity fund. It was Optum. After UnitedHealth’s provider arm bought Oregon Medical Group in 2020, 32 physicians left the group in two years by the Lane County Medical Society’s count, and patients, thousands of them by local lawmakers’ estimates, were left to find new doctors on their own. Two Eugene legislators pressed Optum in writing over the disruption, and Optum agreed not to enforce its physician noncompetes in Oregon. The Legislature then answered with a law aimed at corporate control of medical practice generally, not at private equity alone.
I’ve written about what SB 951 means for the physician practice management model (TL;DR: it’s broken). The bigger story is what happened next: other states started copying it.
At least 15 states now require notice of healthcare transactions, and the pace is accelerating: eight states enacted new transaction laws or regulations in 2026 alone. The laws fall into three tiers.
The first tier is time and transparency. Most states ask for 30 to 90 days’ notice, and some publish what they receive. New York posts a summary of each deal for public comment before it closes, and Washington’s attorney general publishes a quarterly list of pending and completed deals. Massachusetts cannot block a transaction, but its Health Policy Commission can hold one for roughly six months while it studies cost and market impact, and the deal can close only 30 days after the final report. Deal terms, ownership structures and investor names that used to stay private can end up in the local paper before closing.
The second tier is permission. Oregon can approve, condition or reject a deal after a review that can run 180 days. Maine will have the same power over private equity and MSO acquisitions starting January 1, 2027. Minnesota’s attorney general can go to court to unwind a transaction that is contrary to the public interest.
The third tier, and the one that matters most, is control. Oregon bars MSOs from controlling the practices they serve. California and Vermont now bar private equity groups and hedge funds from interfering with clinical judgment, standards or staffing. Hospitals face their own limits: Massachusetts won’t license a hospital whose main campus is leased from a REIT, Connecticut will bar main-campus sale-leasebacks from July 2027 unless the hospital is in financial distress, and Delaware has barred for-profit acquisitions of nonprofit hospitals through mid-2028.
Two things stand out in the pattern. Outright bans on private equity ownership have failed; Maine’s hospital moratorium expired in June 2026, and Vermont dropped an ownership restriction in favor of limits on investor influence. What passes instead is regulation of operational control, which is more practical and, in some ways, harder to plan around. And the idea has reached Washington: the Stop Corporate Takeovers of Physicians Act, introduced in September 2026 and modeled on Oregon’s law, is unlikely to advance in this Congress, but it tells legislators in every other state where the line is moving.
Healthcare investors have always lived with regulation. But the risks we priced were federal, national and slow-moving. Every bidder faced them equally, and there was usually time to see them coming. The state laws differ in five ways.
They require permission, deal by deal. A middle-market acquisition that once closed on a negotiated schedule may now wait 30 to 180 days for a state to look at it, and in some states the state can say no.
They reach backward. SB 951 applies to existing MSOs by 2029. Investors who closed under the old rules are being asked to restructure platforms they already own. Most PE-backed physician platforms run on exactly the structure Oregon targets: a management company that holds the contracts, the cash and the noncompetes, paired with a practice owned by a friendly physician. If other states copy Oregon, many platforms could face restructuring in the middle of a hold period, with no change in strategy or performance.
They form a patchwork, not a standard. Every state defines a covered transaction, a covered investor and “control” a little differently. A platform in five states can face five notice regimes and review clocks, an add-on can trigger a review the platform deal never did, and several laws don’t take effect until 2027, so the map you underwrite today won’t be the map you exit into.
They follow local headlines. Optum’s 2020 purchase in Oregon produced SB 951 five years later. Steward Health Care’s bankruptcy produced Massachusetts’s review law within a year. One bad outcome in one community can change the rules for every investor in that state.
They shrink the buyer pool at exit. The next buyer faces the same reviews. A sponsor that wants certainty of close may pass on a platform concentrated in Oregon or California, or price the delay into its bid. Exit multiples now depend partly on where the business operates.
State legislative risk now belongs in the investment memo next to reimbursement and clinical labor. In practice:
This is not the end of private equity in healthcare. Most of these laws ask for notice, transparency and real physician control, and well-run platforms can meet those standards. Capital will keep flowing to providers that deliver good care at a fair cost.
But the cost of doing a deal has changed for good. It now includes more time, more structural work and more political exposure, and those costs fall hardest on investors who treat healthcare like any other sector. For the first time, state legislatures are a stakeholder in every transaction. The investors who do best will be the ones who plan for that from the first meeting, not the ones who learn it in the middle of a review.
250 Fillmore Street
Denver, CO 80206
50 Milk Street
Boston, MA 02109
970-450-7400
connect@4-cc.com
